logo
logo

Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M

Feb 13, 2024•over 1 year ago

Amount Raised

$147 Million

Round Type

series b

Menlo ParkBiotechnology Research

Investors

Velosity CapitalEventide Asset ManagementMonograph CapitalSurveyor CapitalFrazier Life SciencesSanofi VenturesThe Rise FundTpg Life Sciences InnovationsEnavate SciencesUpmc EnterprisesLeaps By BayerSv Health Investors FundDementia Discovery Fund (Ddf)

Description

Sudo Biosciences announced the second close of its upsized Series B financing, bringing the total raised in the round to $147M. The funding will be used to advance two investigational TYK2 candidates into the clinic this year, including a potential first and best-in-class brain-penetrant TYK2 therapeutic for multiple sclerosis, Alzheimer’s Disease, and ALS, as well as a potential first and best-in-class topical TYK2 inhibitor for psoriasis and other immune-mediated dermatologic diseases.

Company Information

Company

Sudo Biosciences

Location

Menlo Park, California, United States

About

Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel, best-in-class medicines to transform patients’ lives. Our lead programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions.

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People